Search Results - "Juergens, R."

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC by Socinski, M., Creelan, B., Horn, L., Reck, M., Paz-Ares, L., Steins, M., Felip, E., van den Heuvel, M., Ciuleanu, T.E., Badin, F., Ready, N., Hiltermann, T.J.N., Nair, S., Juergens, R., Peters, S., Minenza, E., Geese, W.J., Bhagavatheeswaran, P., Chen, A., Carbone, D.P.

Get full text

Intermittent Hypoxia Contributes to the Lung Damage by Increased Oxidative Stress, Inflammation, and Disbalance in Protease/Antiprotease System by Tuleta, I., Stöckigt, F., Juergens, U. R., Pizarro, C., Schrickel, J. W., Kristiansen, G., Nickenig, G., Skowasch, D.

“…Introduction Intermittent hypoxia as a surrogate of obstructive sleep apnea is associated with different cardiovascular complications. However, the effects of…”
Get full text

Immuno-oncology-the new paradigm of lung cancer treatment by Dawe, D E, Harlos, C H, Juergens, R A

“…Systemic therapy is an essential part of treatment for all patients with small-cell lung cancer (sclc) and for most patients with non-small-cell lung cancer…”
Get full text

Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC by Melosky, B., Chu, Q., Juergens, R.A., Leighl, N., Ionescu, D., Tsao, M.-S., McLeod, D., Hirsh, V.

“…•Checkpoint inhibitors re-engage the immune system to fight cancer.•Survival benefits are confirmed for first- and later line advanced NSCLC.•Immune-related…”
Get full text

Podokinetic circular vection: characteristics and interaction with optokinetic circular vection by Becker, W., Kliegl, K., Kassubek, J., Jürgens, R.

“…Stabilising horizontal body orientation in space without sight on a rotating platform by holding to a stationary structure and circular ‘treadmill’ stepping in…”
Get full text

Canadian consensus: a new systemic treatment algorithm for advanced EGFR- mutated non-small-cell lung cancer by Melosky, B, Banerji, S, Blais, N, Chu, Q, Juergens, R, Leighl, N B, Liu, G, Cheema, P

“…Multiple clinical trials for the treatment of advanced mutated non-small-cell lung cancer (nsclc) have recently been reported. As a result, the treatment…”
Get full text

Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort by Juergens, R A, Mariano, C, Jolivet, J, Finn, N, Rothenstein, J, Reaume, M N, Faghih, A, Labbé, C, Owen, S, Shepherd, F A, Villeneuve, J, Romeyer, F, Pettersson, F, Butts, C

“…Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit…”
Get full text

A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol by Spicer, J., Blais, N., Owen, S., Robinson, A.G., Chu, Q., Labbe, C., Shieh, B., Brown-Walker, P., Sederias, J., Jensen, K., Farago, A.F., Tsao, M.-S., Cottrell, T.R., Kidane, B., Laurie, S., Juergens, R., Bradbury, P.A., Tu, W., Gaudreau, P.-O.

“…Molecularly targeted agents are increasingly being studied in the treatment of early-stage non-small cell lung cancer (NSCLC) to try and improve cure. However,…”
Get full text

The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review by Colomer-Lahiguera, S., Bryant-Lukosius, D., Rietkoetter, S., Martelli, L., Ribi, K., Orcurto, A., Juergens, R., Eicher, M.

Get full text

Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial by JUERGENS, U.R, DETHLEFSEN, U, STEINKAMP, G, GILLISSEN, A, REPGES, R, VETTER, H

“…Airway hypersecretion is mediated by increased release of inflammatory mediators and can be improved by inhibition of mediator production. We have recently…”
Get full text

Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts by Haag, S, Matthiesen, S, Juergens, U. R, Racke, K

“…Clinical observations indicate that in chronic obstructive pulmonary disease patients, the long-acting muscarinic antagonist tiotropium delays decline in…”
Get full text

Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice by Frueh, M., Rahma, O.E., Pachynski, R.K., Mazieres, J., Goldschmidt, J., Ton, T.G.N., Mhatre, S.K., Chuo, C.-Y., Martinalbo, J., Davies, J., Juergens, R.

Get full text

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer by Laurie, S A, Banerji, S, Blais, N, Brule, S, Cheema, P K, Cheung, P, Daaboul, N, Hao, D, Hirsh, V, Juergens, R, Laskin, J, Leighl, N, MacRae, R, Nicholas, G, Roberge, D, Rothenstein, J, Stewart, D J, Tsao, M S

“…Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (nsclc) presenting with rarer clinical scenarios, including…”
Get full text

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens by Goffin, J. R., Nicholas, G., Mates, M., Tu, D., Chen, E., Laurie, S. A., Juergens, R., Robinson, A., Goss, G., Reaume, M., Sun, S., Christink, K., Maize, C., MacFarlan, S., Sun, X., Ritter, H., Seymour, L., Bradbury, P. A.

“…Summary Introduction Selumetinib (AZD6244, ARRY-142886) is a potent inhibitor of MEK1/2, thereby inhibiting phosphorylation of ERK2. We investigated the…”
Get full text

Optokinetic circular vection: a test of visual–vestibular conflict models of vection nascensy by Jürgens, R., Kliegl, K., Kassubek, J., Becker, W.

“…The propensity to experience circular vection (the illusory perception of self-turning evoked by a rotating scene, CV) as reflected by its onset latency…”
Get full text

Standardizing biomarker testing for Canadian patients with advanced lung cancer by Melosky, B, Blais, N, Cheema, P, Couture, C, Juergens, R, Kamel-Reid, S, Tsao, M-S, Wheatley-Price, P, Xu, Z, Ionescu, D N

“…The development and approval of both targeted and immune therapies for patients with advanced non-small cell lung cancer (nsclc) has significantly improved…”
Get full text

Pro‐fibrotic processes in human lung fibroblasts are driven by an autocrine/paracrine endothelinergic system by Ahmedat, AS, Warnken, M, Seemann, WK, Mohr, K, Kostenis, E, Juergens, UR, Racké, K

“…Background and Purpose Since endothelin (ET) may act as pro‐fibrotic mediator, expression and release of ET isoforms, their receptors and potential…”
Get full text

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies by Nehra, J., Bradbury, P. A., Ellis, P. M., Laskin, J., Kollmannsberger, C., Hao, D., Juergens, R. A., Goss, G., Wheatley-Price, P., Hotte, S. J., Gelmon, K., Tinker, A. V., Brown-Walker, P., Gauthier, I., Tu, D., Song, X., Khan, A., Seymour, Lesley, Smoragiewicz, M.

“…Summary Background The IND.226 study was a phase Ib study to determine the recommended phase II dose of durvalumab + tremelimumab in combination with standard…”
Get full text

Management of EGFR- mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective by Cabanero, M, Sangha, R, Sheffield, B S, Sukhai, M, Pakkal, M, Kamel-Reid, S, Karsan, A, Ionescu, D, Juergens, R A, Butts, C, Tsao, M S

“…Starting in the early 2000s, non-small-cell lung cancer (nsclc) subtypes have evolved from being histologically described to molecularly defined. Management of…”
Get full text

Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes by Juergens, Uwe R., Engelen, Tanja, Racké, Kurt, Stöber, Meinolf, Gillissen, Adrian, Vetter, Hans

“…The therapeutic value of secretolytic agents in COPD and asthma is still disputed. For this reason, in a preclinical study we aimed to test the potential…”
Get full text